[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:grade-3a-follicular-lymphoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":23,"states":24},"Grade 3a Follicular Lymphoma",2,1,[8,16],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06948786","Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed\u002FRefractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial",[12],"Phase 2","RECRUITING","2026-08-26T02:17:32.059863Z","2026-07-05T05:32:16.721320Z",{"nct_id":17,"title":18,"phases":19,"status":20,"updated_at":21,"content_modified":22},"NCT07731789","Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma",[12],"NOT_YET_RECRUITING","2026-08-26T02:17:48.768272Z","2026-07-30T01:46:14.455065Z",[],[]]